A diabulimia ou dieta da insulina é um transtorno alimentar como prática da omissão ou diminuição intencional da dose de insulina, com o objetivo de perder peso. Objetivo: Realizar uma revisão sistêmica sobre o tema “diabulimia” com o objetivo de entender os aspectos gerais desse transtorno alimentar. Metodologia: Foram utilizadas para pesquisa 5 plataformas de literaturas científicas como base de dados, sendo elas: Scientific Eletronic Library On-line (SciELO), Lilacs, PubMed, Cochrane Library e Google Scholar. Foram utilizadas literaturas publicadas nas línguas portuguesa e inglesa, entre os anos de 2018-2021. Resultado e discussão: A partir dos estudos, foi possível perceber que a diabulimia pode provocar diversas complicações no paciente à longo prazo, podendo inclusive reduzir a expectativa de vida, por envolver o metabolismo da glicose. Sendo assim, é de fundamental importância que os pacientes com DM1 tenham acompanhamento contínuo e efetivo com endocrinologistas, psicólogos, educadores físicos e nutricionistas visando um apoio multidisciplinar. Conclusão: A principal sintomatologia relacionada às complicações da diabulimia, através da pesquisa sistemática do presente trabalho, foi a perda de peso. Além disso, entre os principais fatores que fazem o paciente com diabetes realizar tal prática alimentar pode ser citado a insatisfação com o corpo e a diminuição da autoestima.
Wernicke's encephalopathy (WE) and Korsakoff syndrome (KS) are distinct neurological disorders that may have overlapping clinical features. Due to the overlap, they are collectively referred to as Wernicke-Korsakoff syndrome. WE has been associated with thiamine-induced diencephalic and midbrain dysfunction. WE usually presents with confusion, ophthalmoplegia, nystagmus, and gait ataxia (Wernicke's triad), although they do not always occur together. Although WE occurs mainly in alcoholics, other etiologies must also be considered, such as after bariatric surgery. Early diagnosis and intravenous thiamine therapy are essential to prevent WE complications and reduce morbidity and mortality. Therefore, allowing physicians and patients to understand WE is crucial for early diagnosis and treatment. Therefore, the narrative review aims to provide the latest information on WE by reviewing articles published between April 2015 and April 2022 on the etiology, pathophysiology, diagnosis, and management updates of WE. Literature searches were performed using EMBASE, PubMed, Google Scholar, Google, and Scopus search engines.
Introduction: Children's multisystem inflammatory syndrome (MIS-C), also known as pediatric inflammatory multisystem syndrome, is a dangerous new childhood illness that is temporarily associated with coronavirus disease 2019 (COVID-19). Our aim was to describe the typical presentation and outcomes of children diagnosed with this hyperinflammatory condition. Method: We conducted a systematic review to report the clinical signs and symptoms, laboratory findings, imaging results, and outcomes of subjects with MIS-C. We searched four medical databases to encompass studies featuring 2020 MIS-C. Results: Fever was documented in nearly all patients (99.4%), usually lasting at least 5 days (27.0%). Most (85.6%) had gastrointestinal symptoms, mainly abdominal pain (58.4%), vomiting (57.5%) and diarrhea (50.4%). Cardiovascular manifestations were found in 79.3% of patients (307/387). Tachycardia (194/253; 76.7%), hemodynamic shock or hypotension (416/695; 59.9%), myocarditis (128/309; 41.4%) and mild or moderate decrease in left ventricular ejection fraction (LVEF between 30 and 55%; 40.4%) were frequently observed cardiovascular abnormalities. Discussion: Children typically show signs/symptoms of MIS-C three to four weeks after infection with COVID-19 and many rapidly progress to shock and cardiorespiratory failure. Children will generally survive this hyperinflammatory condition with the administration of IVIG, steroids, a multidisciplinary team of healthcare professionals, and in some cases, immunomodulatory agents. Conclusion: More epidemiological, clinical, immunological and genetic research is needed, as well as long-term follow-up studies of patients with PIMS-TS/MIS(-C).